Methodology article **[Open Access](http://www.biomedcentral.com/info/about/charter/)**

A novel method for evaluation and screening of caspase inhibitory peptides by the amino acid positional fitness score

Atsushi Yoshimori1, Ryoko Takasawa2 and Sei-ichi Tanuma*1,2,3

Address: 1Research Institute for Biological Sciences, Tokyo University of Science, 2669 Yamazaki Noda, Chiba 278-0022, Japan, 2Genome and Drug Research Center, Tokyo University of Science, 2641 Yamazaki Noda, Chiba 278-8510, Japan and 3Department of Biochemistry, Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki Noda, Chiba 278-8510, Japan

Email: Atsushi Yoshimori - yosimori@rs.noda.tus.ac.jp; Ryoko Takasawa - takasawa@rs.noda.tus.ac.jp; Seiichi Tanuma* - tanuma@rs.noda.tus.ac.jp

* Corresponding author

Published: 22 May 2004

BMC Pharmacology 2004, **4**:7 doi:10.1186/1471-2210-4-7

[This article is available from: http://www.biomedcentral.com/1471-2210/4/7](http://www.biomedcentral.com/1471-2210/4/7)

© 2004 Yoshimori et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Received: 29 December 2003 Accepted: 22 May 2004

Abstract

Background: Since caspases are key executioners of apoptosis in cases of severe diseases including neurodegenerative disorders such as Alzheimer's disease and Huntington's disease, and viral infection diseases such as AIDS and hepatitis, potent and specific inhibitors of caspases have clinical potential. A series of peptide inhibitors has been designed based on cleavage sites of substrate proteins. However, these peptides are not necessarily the most potent to each caspase. Moreover, so far, it has proved to be difficult to design potent and specific peptide inhibitors of each caspase from sequence data of known cleavage sites in substrate proteins. We have attempted to develop a computational screening system for rapid selection of potent and specific peptide inhibitors from a comprehensive peptide library.

Results: We developed a new method for rapid evaluation and screening of peptide inhibitors based on Amino acid Positional Fitness (APF) score. By using this score, all known peptide inhibitors of each caspases-3,-7,-8, and -9 were rapidly selected in their enriched libraries. In this libraries, there were good correlations between predicted binding affinities of the known peptide inhibitors and their experimental Ki values. Furthermore, a novel potent peptide inhibitor, Ac-DNLD-CHO, for caspase-3 was able to be designed by this method. To our knowledge, DNLD is a first reported caspase-3 inhibitory peptide identified by using the computational screening strategy.

Conclusion: Our new method for rapid screening of peptide inhibitors using APF score is an efficient strategy to select potent and specific peptide inhibitors from a comprehensive peptide library. Thus, the APF method has the potential to become a valuable approach for the discovery of the most effective peptide inhibitors. Moreover, it is anticipated that these peptide inhibitors can serve as leads for further drug design and optimization of small molecular inhibitors.

Background

Caspases are cysteine aspartyl proteases that play critical roles during the execution of apoptosis [1-5]. Caspases have been found in organisms ranging from C. *elegans* to humans. The 14 types of caspase (named caspase-1 to caspase-14) identified so far in mammals are suggested to play distinct roles in apoptosis and inflammation. The main caspase cascades are catalyzed by caspases-8 and -9

(initiator caspases) and caspases-3 and -7 (executioner caspases) [4,5]. The disregulation of caspase cascade activation is suggested to be involved as a key factor for the development of a variety of diseases, including neurodegenerative disorders and cancers [6-9].

Caspases share similarities in amino acid sequence, structure and substrate specificity, and are characterized by an almost absolute specificity in the active sites for aspartic acid in the P_1 position of substrate proteins. Each active site contains a positively charged S_1 subsite that binds the negatively charged P_1 aspartate on the substrate [10-13]. This S_1 binding site is highly conserved; therefore, all caspases cleave solely after aspartate residues. Recognition of at least four amino acids (P_1-P_4) in the cleavage sites is also a necessary requirement for efficient catalysis. Individual caspases have been shown to have structural differences in the predicted S_2-S_4 substrate binding sites which vary significantly, resulting in varied substrate specificities for the P_2-P_4 positions, despite an absolute requirement for aspartate in the P_1 position [10-16].

The interactions between caspases and their target substrate proteins are highly flexible, so that many caspase inhibitory peptides, which are derived from natural substrates, are recognized by several members of the caspase family. For instance, the sequence DEVD within poly(ADP-ribose) polymerase (PARP) [17] is known to be recognized and cleaved by caspase-3, and it has been applied to creating the tetrapeptide inhibitor Ac-DEVD-CHO. However, Ac-DEVD-CHO also shows similar inhibitory activity toward caspases-7, and -8 as well as caspase-3 [18]. Therefore, it is difficult to design selective caspase inhibitory peptides based on the sequence of known cleavage sites.

To identify the sequence with the highest binding affinity for each caspase, the X-X-X-D (X any of the 20 amino acids) peptide sequence motif is utilized for Structure-Based Virtual Screening (SBVS), which involves 203, i.e., 8000, ∆G_{bind} evaluations. In order to show each amino acid position clearly, the X-X-X-D motif is expressed as P_4 - P_3-P_2-D . In SBVS using a library consisting of hundreds of thousands small molecules, it is necessary to limit the computing time per compound to at most 1 min. However, even side chains of a peptide with only 4 amino acids have a maximum of 20 rotational bonds. In flexible docking using AutoDock3.0 [19] with default parameters, a computing time of about 20 min per 4-amino acid peptide on a COMPAQ Alphastation DS20E (double 833 MHz processors and 1024 MB of memory) is required. In the case of the design of a 5-amino acid peptide, it is necessary to carry out 3.2 million ΔG_{bind} calculations, so that comprehensive peptide screening is practically difficult. Moreover, the computing time for ΔG_{bind} calculation can

be traded off against accuracy. Therefore, the most problematic aspect of ΔG_{bind} calculation is time-consumption for SBVS.

Alternatively, various pattern-recognition techniques have been used to analyze peptide cleavage data [20,21]. A statistical technique has been used to calculate binding free energy in the analysis of resistance-evading, peptide mimetic inhibitors of HIV-1 protease [22]. These types of methods are enough to make potent peptide screening tractable. However, many experimental data points are needed to construct a highly precise scoring function.

In the present study, we have developed a new computational screening strategy based on Amino Acid Positional Fitness (APF) score for rapid evaluation of peptides interacting specifically with a target protein molecule. In our system, 1 to 10% of peptides are extracted at random from a comprehensive peptide library. The ΔG_{bind} s between the extracted peptides and the target protein are calculated using AutoDock3.0, and then the data are transferred to obtain the APF score for each amino acid position (for example; P_2 , P_3 , and P_4 in caspases) using a statistical technique. Consequently, this score is able to evaluate rapidly the ΔG_{bind} s of all peptides in the comprehensive peptide library. We show here the usefulness of this APF method for the screening of potent and specific peptide inhibitors of main caspase family members.

Results and Discussion *Evaluation of binding modes and affinities of caspase inhibitory peptides by AutoDock3.0*

One of goals of this work is the development of a simple and fast scoring function (APF score matrix) for the prediction of binding affinities of peptides against target protein molecules. The APF score matrix is derived from the predicted binding modes and affinities based on a standard docking program, AutoDock3.0. It is, therefore, important to verify the docking results of AutoDock3.0. Initially, we used Root of Mean Squared Deviation (RMSD) value as an indicator of the quality of the predicted binding modes. The RMSD was determined for the atomic positions between the predicted binding mode of peptide and native one as found in the crystal structure. The crystal structures of caspase-3 (1PAU), caspase-7 $(1F1J)$, caspase-8 $(1QTN)$, and caspase-9 $(1JXQ)$ were used to validate the quality of predicted binding modes.

AutoDock3.0 uses a rapid grid-based lookup method for energy evaluation. The use of interaction energy grids allows the use of a sophisticated empirical free energy force field, while greatly reducing the computational demands of the docking simulation. In this study, the Lamarckian Genetic Algorithm (LGA), which combines a genetic algorithm and a local search algorithm, was used

Effects of the number of energy evaluations on th **Figure 1** e quality of the predicted binding mode of peptide

Effects of the number of energy evaluations on the quality of the predicted binding mode of peptide. The RMSD value is used as an indicator of the quality of the predicted binding mode, and is determined for the atomic positions of the predicted binding mode of peptide and the native one as found in the crystal structure. (a) caspase-3/DEVD, (b) caspase-7/DEVD, (c) caspase-8/IETD, (d) caspse-9/LEHD. During the docking, the main chain angles of peptides are fixed (◆) or flexible (■).

as the search method. Since the docking parameters of AutoDock3.0 affect the qualities of predicted binding modes and affinities, the number of energy evaluations is an important docking parameters [23]. So, we investigated the effect of the number of energy evaluations on the quality of the predicted binding mode of peptide (Figure 1). Other docking parameters were set to the default values. In the case of a fixed main chain, the RMSD values were roughly constant and less than 2 Å in all cases. In contrast, when all of rotational torsion angles were flexible (full flexible), the number of energy evaluations does have an influence. Below 1.5 million energy evaluations,

the RMSD values of caspase-7/DEVD were more than 2.0 Å (Figure 1b). More than 3 million energy evaluations are required to predict the binding mode of peptide with an RMSD of less than 2.0 Å with respect to the crystal structures of the four caspases.

In Structure-Based Virtual Screening (SBVS), the computing time for evaluation of binding affinity is an important factor, as well as computational accuracy. Figure 2 shows the relationship between the number of energy evaluations and the average of the computing time on COMPAQ Alphastation DS20E. For example, in 0.7 million energy

Effects of the number of energy evaluations on the computing time. The computing times were measured in the various number of energy evaluations. During the docking, the main chain angles of peptides are fixed (◆) or flexible (■).

evaluations and with a fixed main chain, the average computing time was about 10 min (Figure 2). This is reasonable time per peptide for constructing the APF score matrix. However, fixation of the main chain during docking may affect the quality of docking results of inhibitory peptides with arbitrary amino acid sequences. So, we compared our docking results of well-known peptide inhibitors of caspases-3,-7,-8, and -9 with their experimental data (Table [1](#page-3-0)) previously reported (Table [2\)](#page-4-0). In this experiment, to generate the initial conformations of these peptides, the crystallographic structures were used for the main chain coordinate of the inhibitory peptides, and then the side chains were added. Moreover, in order to exclude van der Waals contacts of side chains, the TINKER software package [24] was used and energy minimization using the Amber94 forcefield was performed. During the minimization, the main chain atoms were fixed and RMSD gradient limits were 0.01. Kollman atom charges were assigned and the rotational bonds of the peptides were defined with AutoTors [19]. Thus, the docking parameters and conditions are determined as follows: the number of energy evaluations is 0.7 million, other parameters are default values, and main chain angles are fixed.

To verify the accuracy of the docking results, we analyzed correlation coefficients between ΔG_{bind} s (predicted) and log Ki values (observed). Peptide inhibitors with Ki values of >10,000 nM were set up the value of 10,000 nM. As shown in Table [2,](#page-4-0) the correlation coefficients were 0.75 (caspase-3), 0.83 (caspase-7), 0.95 (caspase-8), and 0.96 (caspase-9). The results show good correlations between predicted ΔG_{bind} values by AutoDock3.0 and experimental Ki values. These observation imply that our docking parameters and conditions (0.7 million energy evaluations and fixed main chain) are reasonable for predicting binding modes and affinities of caspase inhibitory peptides.

Construction of APF score matrix

As a first attempt, APF score matrices for caspases-3, -7, -8, and -9 were constructed. The APF score matrix shows the P_2-P_4 preferences of a caspase (Figure [3\)](#page-5-0), and if a high correlation coefficient is observed between the APF score derived from APF score matrix and ΔG_{bind} , the APF score enables the rapid prediction of $\Delta G_{\rm bind}$ between a caspase and arbitrary peptides. Figure [4](#page-6-0) shows the scatter plot of APF score *vs* ΔG_{bind} in the analysis library and prediction library. The APF score of caspase-3 showed a preference for P_4 : D, $V > Q$, P_3 : $E > L > P$ and P_2 : $V > E > P$ (Figure [3a](#page-5-0)). The results obtained for caspase-3 indicate that the preferred recognition motif for this enzyme is (D/V)EVD. Interestingly, DEVD is a cleavage site within PARP [17] and is also the optimal recognition sequence identified from a positional scanning synthetic combinatorial library (PS-SCL) [14]. The correlation coefficient for the caspase-3 analysis library was -0.71 (Figure [4](#page-6-0)a). To verify the predictability of APF score, the correlation analysis was performed using a prediction library comprising of 40 peptides. The correlation coefficient was -0.64 (Figure [4a](#page-6-0)).

Since the APF score matrix of caspase-7 showed a preference for P_4 : $D > E > C$, P_3 : $F > E > D$, P_2 : $P > I$, $S > L$, the preferred recognition motif for this enzyme is DFPD (Figure [3b](#page-5-0)). DEVD, known as the optimal recognition sequence, was not shown to be a sequence with the highest APF score from the APF score matrix. However, a good correlation coefficient between APF score and ΔG_{bind} was confirmed (Figure [4b](#page-6-0)). Although known optimal recognition sequences for caspase-8 and caspase-9 were not shown from the APF score matrix to be sequences with the highest APF score, the correlation coefficients between APF score and $\Delta G_{\rm bind}$ in the analysis library were -0.68 and -0.76, respectively (Figure [4](#page-6-0)c and [4d](#page-6-0)).

APF score matrices of caspases. The APF score matrices indicate the interaction preferences of amino acids with (a) caspase-3, (b) caspase-7, (c) caspase-8, and (d) caspase-9 at each position (P_4-P_2) . If an APF score is greater than 0, the amino acid tends to be favored at a given position. ΔG_{th} (threshold value of ΔG_{bind}) of caspases-3, -7, -8, and -9 are -11.05, -10.69, -11.03, and -12.12 kcal/mol, respectively.

The scatter of APF score 4 for the Analysis library and Prediction library and Pr

 ${\sf The \ scatter\ of\ APF\ score}$ *vs* $\Delta G_{\sf bind}$ for the Analysis library and Prediction library. The solid line is the result of a linear regression fit, and r denotes correlation coefficient. (a) caspase-3, (b) caspase-7, (c) caspase-8, and (d) caspas-9.

The scatter of the APF score *vs* **log Ki for the peptides in** Table 1. The solid line is the result of a linear regression fit, and r denotes correlation coefficient. (a) caspase-3, (b) caspase-7, (c) caspase-8, and (d) caspas-9.

Consequently, it is revealed that the APF score matrices of all caspases have the ability to predict ΔG_{bind} , although known optimal recognition sequences for caspases-7, -8, and -9 were not shown directly.

Prediction of binding affinity of caspase peptide inhibitors A binding affinity prediction for peptide inhibitors for which experimental data (Ki) have been reported [18] was performed using APF score matrix. The inhibition of caspases by peptide inhibitors is shown in Table [1](#page-3-0). Because APF score can predict only the binding affinity of the peptide sequence in the inhibitor, the effects of Ac-, Boc- and -CHO are not taken into account. Peptide inhibitors with Ki values of >10,000 nM were set to the value of 10,000

nM. The correlation coefficient between log Ki values and APF score of caspase-3 was -0.69 (Figure 5a). These five peptides are not included in the analysis library (data not shown). Caspase-3 is inhibited by peptides in the following order: DEVD > AEVD > IETD > WEHD > YVAD. The APF scores of these peptides are in the same order.

The correlation coefficients between log Ki values and APF scores of caspase-7 and caspase-8 were -0.77 and -0.82, respectively (Figure 5b and 5c). When WEHD was omitted from the correlation analysis of caspase-9, the correlation coefficient was -0.86 (Figure 5d). In comparison, the APF score of LEHD, which is utilized as a selective inhibitor of caspase-9, was 0.44. This score means that LEHD has a

high binding affinity for caspase-9. Meanwhile, the APF score of WEHD was 0.59; therefore, it is predicted that WEHD also has a high binding affinity for caspase-9. However, the reported Ki for WEHD is not low (508 nM). APF score of a peptide is the sum of the position-specific scores of the component amino acids, and it is also assumed that each amino acid within a peptide contributes to recognition almost independently. The reason why WEHD does not has low Ki value may be improper interaction of amino acid residues in the peptide.

Construction of enriched library

The locations of inhibitory peptides (Table [1\)](#page-3-0) in the sorted comprehensive peptide libraries are shown in Figure [6](#page-9-0). All inhibitory peptides with Ki values less than 2 nM were located within the top 400 peptides in the libraries, equivalent to 5% of the comprehensive libraries. Therefore, potent peptide inhibitors are considerably enriched. Here, the enriched library is defined as the top 5% of the library. Figure [7](#page-10-0) shows schematic overview of the APF method for constructing of enriched library.

Since the sequences of DEVD, DEPD, DELD, and DGPD, which are cleavage sites for caspase-3, also satisfy the condition of being in the top 5% of the library, it is expected that these sequences have a high binding affinity for caspase-3 (DEVD is already known as an inhibitory peptide, Ac-DEVD-CHO etc.). Meanwhile, the sequences of WEHD and YVAD have high Ki values, 1960 nM and >10,000 nM, respectively. These sequences are located at position 6506 (WEHD) and 7322 (YVAD) in the library. The sequences of DEVD, AEVD, and IETD have low Ki values for caspase-8, 0.92 nM, 1.6 nM, and 1.05 nM, respectively. The library of caspase-8 also reflects the high binding affinities of these sequences, positions of 125, 228, and 328, respectively.

We, therefore, believe that peptides with high affinities for each caspase can be efficiently screened from the enriched library as compared with comprehensive peptide libraries.

Design of a novel caspase-3 inhibitory peptide

To prove the above assumption, we tried to design of a novel caspase-3 inhibitory peptide from its enriched library derived from the APF score. Initially, 400 peptides in the enriched library were docked into the active site of caspase-3 and their ΔG_{bind} were calculated by AutoDock3.0. During the docking, the number of energy evaluations was 0.7 million, main chain angles were fixed, and other parameters were default values. Figure [8](#page-11-0) shows the scatter of APF score *vs* ΔG_{bind} for the 400 peptides from the enriched library and randomly selected 400 peptides from the non-enriched library (except the 400 peptides from the comprehensive peptide library). As expected, the 400 peptides in the enriched library had low ΔG_{bind} (average ΔG_{bind} = -15.47 kcal/mol) as compared with that of peptides in the non-enriched library (average ΔG_{bind} = -13.66 kcal/mol).

Finally, the top 80 peptides (1% of comprehensive peptide library) with low ΔG_{bind} in the 400 peptides of enriched library were docked into the active site of caspase-3. During the docking, the number of energy evaluations was 3 million, all of rotational torsion angles were flexible, and other parameters were default values. Ten predicted potent inhibitory peptides of caspase-3 are summarized in Table [3.](#page-12-0) The most potent peptide sequence was predicted as DEVD (ΔG_{bind} = -16.15 kcal/mol). DELD is the known cleavage site of D4-GDP dissociation inhibitor [25]. Seven of the ten peptides have Glu in the P_3 position. Many of the well-known peptide inhibitors of caspases (see Table [1\)](#page-3-0) also have Glu in the P_3 position. Interestingly, only DNLD has Asn in the P_3 position. Furthermore, at present, no peptide inhibitors or cleavage site in the natural substrates of caspase-3 are known to have Asn in the P_3 position.

Inhibitory effect of DNLD on caspase-3 and its binding mode

To examine the inhibitory effect of DNLD on caspase-3 activity, recombinant active caspase-3 was treated with various concentrations of Ac-DNLD-CHO. As shown in Figure [9](#page-12-1), Ac-DNLD-CHO inhibited caspase-3 in a dosedependent manner. At 30 nM Ac-DNLD-CHO caused the inhibition of caspase-3 activity in more than 90% of the control. The IC_{50} value was calculated to be 3.17 nM. The potency of Ac-DNLD-CHO was slightly weak than that of a well-known peptide inhibitor, Ac-DEVD-CHO (IC_{50} = 1.34 nM, see Figure [9](#page-12-1)).

To obtain a better understanding of how these two peptide inhibitors interact with caspase-3, the structural model for the complex of DNLD with caspase-3 active pocket was predicted by AutoDock3.0 (Figure [10\)](#page-13-0). We inspect the important interactions between the caspase-3 active site and the peptide inhibitors: (i) the Leu (P_2) in DNLD forms tight hydrophobic interactions with Tyr204, Trp206, and Phe256 as well as the Val (P_2) in DEVD; (ii) the Asn (P_3) in DNLD forms one hydrogen bond with Ser209, but the Glu (P_3) in DEVD forms two hydrogen bond with Arg207 and Ser209. These differences may affect their inhibitory potencies and/or specificities against caspase-3.

Conclusions

In the present study, we have developed a new *in silico* strategy based on APF score for rapid evaluation and screening of binding peptide to a target protein molecule. In the Structure-Based Virtual Screening, the computational calculation time of ΔG_{bind} is an important

The locations of peptides (from Table 1) an pase-3, (b) caspase-7, (c) caspase-8, and (d) caspase-9 **Figure 6** d sequences of cleavage sites in the sorted comprehensive peptide libraries (a) cas-

The locations of peptides (from Table 1) and sequences of cleavage sites in the sorted comprehensive peptide libraries (a) caspase-3, (b) caspase-7, (c) caspase-8, and (d) caspase-9. Hatched squares show the Enriched libraries. Columns of inhibitors show ranking, sequence, APF score and Ki, column of cleavage sites shows ranking, sequence, APF score and substrate proteins, and column of optimal sequence shows ranking, sequence, and APF score. These cleavage sites of caspase-3 have been published elsewhere [17,25,29-36]. The optimal recognition sequences are identified from PS-SCL [14].

Schematic overview of the APF method. Step1: A comprehensive peptide library comprising 8000 peptides is constructed. 360 peptides are extracted at random from the comprehensive peptide library and placed in the Analysis library. In a similar manner, 40 peptides are placed in the Prediction library. Step2: The binding free energies of the peptides extracted at random in Step1 are calculated using AutoDock3.0. Step3: The APF score matrix derived from the Analysis library are constructed using equation [1]. Moreover, prediction capability is validated by the APF score matrix against the peptides in the Prediction library. Step4: An Enriched library is constructed according to the APF score derived from the APF score matrix.

factor as well as the computational accuracy. On a common day workstation, it is difficult to predict an appropriate binding mode and binding free energy for a peptide, which has 20 to 30 rotational bonds, against a target protein within a few minutes. Meanwhile, methods for constructing scoring functions from experimental cleavage data are rapid enough to predict binding affinities. However, many experimental data points are required to construct a precise scoring function.

The scatter of APF score *vs* ∆Gbind **Figure 8** for 400 peptides in the enriched library and 400 peptides in the non-enriched library The scatter of APF score *vs* ΔG_{bind} for 400 peptides in the enriched library and 400 peptides in the non**enriched library.** The scatter denotes correlation of APF score and ∆G_{bind} for 400 peptides in enriched library (●, ▲) and randomly selected 400 peptides in the non-enriched library (♦). 400 peptides in enriched library calculated their ΔG_{bind} by AutoDock3.0, and peptides with low ΔG_{bind} (rank 1–80) denotes circle (●) and other peptides (81–400) denotes triangular (▲). The non-enriched library is comprehensive peptide library except 400 peptides in enriched library.

The APF score developed here allows rapid prediction of peptide binding affinities. The statistical basis of APF score is derived from the calculated $\Delta G_{\rm bind}$ s between randomly extracted peptides and a target caspase using AutoDock3.0. Therefore, our system does not require experimental data for constructing a scoring function. It should be noted that the binding affinities of caspase inhibitory peptides derived rapidly from the APF score correlate well with their reported inhibitory kinetics, and that all peptides with Ki values less than 2 nM were condensed in the top 5% of the sorted comprehensive peptide libraries.

To prove the utility of this method, an attractive candidate for a new caspase-3 inhibitor in the enriched library was selected by the APF score. Ac-DNLD-CHO, whose sequence is so far not known in any caspase substrate, and has a low ΔG_{bind} , was chosen and its inhibitory activity

	Peptide	ΔG_{bind} (kcal/mol)	APF score
	DEVD	-16.15	0.73
	OEPD	-15.91	0.60
	TEPD	-15.75	0.53
4	DELD	-15.65	0.59
	QELD	-15.63	0.56
6	LEPD	-15.57	0.49
	DNLD	-15.45	0.52
8	DQPD	-15.39	0.54
9	DPFD	-15.16	0.51
$\overline{10}$	NEPD	-14.95	0.50

Table 3: Ten Predicted potent peptide inhibitors of caspase-3

Inhibitory effects of DNLD and DEVD on caspase-3 activity. Caspase-3 was preincubated with various concentrations of Ac-DNLD-CHO (\bullet) or Ac-DEVD-CHO (\circ) , and then the activity of caspase-3 was measured with Ac-DEVDpNA substrate as described (see "Materials and Methods"). The kinetic data presented are the means of three independent experiments.

was measured. As expected, Ac-DNLD-CHO had similar potent inhibitory activity to a well-known inhibitor Ac-DEVD-CHO. Although the system needs further validation, it is likely that by using the APF method, peptides with high affinities can be efficiently selected from the enriched library as compared with random screening.

At present, small peptides have been suggested to have clinical potential, because in specific protein-protein interactions occurred in many signalling pathways, small critical domains on the molecules are revealed to be involved in their biological activities. Furthermore, many peptide ligands exist in living organisms. Thus, new computational methods for the identification of active peptide will be powerful tools for the development of new pharmaceuticals. The APF method developed here is an attractive strategy that could discover novel therapeutic agents.

Methods

Materials

Ac-DNLD-CHO was synthesized by Peptide Institute, Inc. Ac-DEVD-CHO was purchased from Peptide Institute, Inc. Ac-DEVD-pNA and recombinant human caspase-3 were from CALBIOCHEM.

Caspase-3 Inhibition assay

To determine inhibitory potency of Ac-DNLD-CHO against caspase-3, an *in vitro* caspase activity assay was performed. The activity of caspase-3 was measured using Ac-DEVD-pNA as a substrate. One unit of active recombinant human caspase-3 was incubated with peptide inhibitor at indicated concentrations in assay buffer (100 mM NaCl, 50 mM HEPES, 10 mM DTT, 1 mM EDTA, 10% glycerol, and 0.1% CHAPS, pH 7.4) at 25°C for 30 min with shaking in a 96-well assay plate (CORNING). Then, 100 µM of Ac-DEVD-pNA was added to each well and absorbance at 405 nm was measured at 25°C using a 96-well plate reader Wallace 1420 ARVOsx (PerkinElmer) at 1 min intervals for 60 min.

Preparation of caspase/inhibitory peptide complex structure

In this study, we evaluated the binding mode and affinity of caspase inhibitory peptides by AutoDock3.0, and then constructed the APF score matrices of caspases-3, -7, -8, and -9. The coordinates of caspases-3, -7, -8, and -9 were obtained from the Protein Data Bank (codes 1PAU, 1F1J, 1QTN, and 1JXQ) [26]. Since the caspase-9 inhibitor in the crystallographic structure is not a 4-amino acid peptide, LEHD, known to be an optimal sequence [14], was

The complex structure of active site of caspase-3 with DNLD or DEVD. Nitrogen, oxygen, and carbon atoms in the active site of caspase-3 are illustrated with blue, red, and grey, respectively. (a) Predicted binding mode of DNLD is shown as yellow. (b) DEVD in crystal structure (PDB, 1PAU) is shown as orange. During the docking of DNLD against caspase-3, the number of energy evaluations was 3 million, all of rotational torsion angles were flexible, and other parameters were default values.

docked against caspase-9 using AutoDock3.0 [19], and the predicted complex structure was used for subsequent analysis. The crystallographic structures including water were deleted, and energy minimization using the TINKER software package [24] was used and energy minimization using the Amber94 forcefield was performed. During the minimization, the RMSD gradient limits were 0.01.

Construction of APF Score matrix

The feature of our computational screening strategy is construction of the Amino acid Positional Fitness (APF) score matrix for a target protein. This score matrix allow us to predict binding affinities between a target protein and peptides rapidly.

Our system comprises four steps as follows (Figure [7](#page-10-0)).

Step 1. Construction of peptide library

To identify the P_2-P_4 preferences of each caspase, we constructed an analysis library with aspartic acid fixed at P_1 and randomized amino acids at P_2-P_4 . In order to analyze the $P_4-P_3-P_2-D$ motif comprehensively, it is necessary to analyze 8000 combinations. In this system, 400 peptides equivalent to 5% of all combinations were extracted at random, and an analysis library consisting of 360 peptides and a prediction library consisting of 40 peptides were prepared. To generate initial conformation for peptides in the analysis and prediction libraries, the main chain coordinates were used for the inhibitory peptides in the crystallographic structures, and the side chains were added. Moreover, in order to exclude VDW contacts of side chains, the TINKER software package [24] was used and energy minimization using the Amber94 forcefield was performed. During the minimization, the main chain atoms were fixed and RMSD gradient limits were 0.01. Kollman atom charges were assigned and the rotational bonds of the peptides were defined with AutoTors [19].

Step 2. Calculation of binding free energy using flexible ligand docking

The ∆G_{bind}s of 400 randomly extracted peptides with a caspase were calculated.

In this study, the main chains of the peptides were fixed and the side chains were made flexible. During the docking, the number of energy evaluations was 0.7 million and other parameters were default values. The predicted binding mode of each peptide with caspase was inspected to determine whether the binding mode was appropriate. In order to arrange a functional group such as CHO on the caspase active site, a suitable binding mode of peptide is important. In generally, good docking solutions have an RMSD of 2.0 Å or less [27], and 3 peptides with Ki value of >10,000 nM dose not have an RMSD of 2.0 Å or less in Table [2.](#page-4-0) Therefore, peptides with 2Å or

more RMSD compared with the peptide inhibitor in the crystallographic structure were defined as not binding to caspases.

Step 3. Construction of APF Score matrix

APF score matrix based on the frequency of appearance of 20 amino acids at each of positions P_4 , P_3 , and P_2 were generated in the analysis library. The APF score for amino acid i at position j is calculated as follows:

$$
APF_{ij} = \log \left(\frac{\rho_{binder}^{ij}}{\rho_{all}^{ij}} \right) \tag{1}
$$

where ρ_{all}^{ij} is the frequency of amino acid i at position j

among peptides in the analysis library, and $\rho_{\text{binder}}^{ij}$ is the frequency of amino acid i at position j among peptides below the threshold value (ΔG_{th}) of binding free energy and RMSD 2 Å in the analysis library.

$$
\rho_{all}^{ij} = \frac{c_{ij}}{n_{all}}
$$
 [2]

$$
\rho_{binder}^{ij} = \frac{c'_{ij}}{n_{binder}}
$$
 [3]

 c_{ii} denotes the number of times amino acid i appears at position j among peptides in the analysis library. n_{all} is the number of peptides in the analysis library. c'_{ii} denotes the number of times amino acids i appears at position j among peptides below the threshold value (ΔG_{th}) of binding free energy and the RMSD 2 Å in an analysis library, and n_{binder} is the number of peptides below the threshold value (ΔG_{th}) and RMSD 2 Å. The range of position j is from 1 to 3, and corresponding to P_2 to P_4 . The range of amino acid i is from 1 to 20, and corresponding to individual amino acids.

By using APF score matrix, it becomes possible to calculate the APF score, which shows the binding affinity of a peptide and a caspase. The APF score of a peptide is given by Equation [4].

$$
APF score = \sum_{i=1}^{20} \sum_{j=1}^{3} c_{ij} APF_{ij}
$$
 [4]

A peptide with the $P_4-P_3-P_2-D$ motif is represented by a 20 \times 3 matrix (c_{ij}) of 0s and 1s, where c_{ij} = 1 if amino acid i is at position j [28].

Correlation analysis of APF score and ΔG_{bind} of peptides consisting in the analysis library was carried out. If a high correlation is observed between APF score and ΔG_{bind} , it becomes possible to predict ΔG_{bind} using APF score. A threshold value (ΔG_{th}) was set up the value that makes the correlation coefficient between APF score and ΔG_{bind} maximal.

Next, correlation analysis between APF score and ∆G_{bind} of peptides involved in a prediction library was carried out. Here, the APF score was calculated by using APF score matrix generated from the analysis library, and the prediction capability was validated.

Step 4. Construction of an enriched library by APF score

It is assumed that potent peptide inhibitors are distributed randomly in the comprehensive peptide library. The APF scores of all peptides in the comprehensive peptide library were calculated using APF score matrix generated from the analysis library. Since a high APF score reflects high binding affinity, peptides in the comprehensive peptide library were sorted in descending order according to their APF score. This operation takes the high affinity peptides, which are distributed throughout the library, condenses them at a higher rank in the library. The enriched library was defined as the top 5% of the sorted comprehensive peptide library.

Authors' contributions

AY implemented most of the algorithms, participated in study design, and wrote the manuscript. RT assisted with study design and performed caspase inhibition assays. ST conceived the study and participated in its design and coordination.

Acknowledgements

We are grateful to Dr. J. W. Ponder for providing the Tinker program and Dr. A. J. Olson for providing the AutoDock3.0 program.

References

- 1. Nicholson DW: **[ICE/CED3-like proteases as therapeutic tar](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9630889)[gets for the control of inappropriate apoptosis.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9630889)** *Nat Biotechnol* 1996, **14:**297-301.
- 2. Salvesen GS, Dixit VM: **[Caspases: intracellular signaling by](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1016/S0092-8674(00)80430-4) [proteolysis](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1016/S0092-8674(00)80430-4)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9390553)** *Cell* 1997, **91:**443-446.
- 3. Cohen GM: **[Caspases: the executioners of apoptosis.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9337844)** *Biochem J* 1997, **326:**1-16.
- 4. Thornberry NA, Lazebnik Y: **[Caspases: enemies within](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1126/science.281.5381.1312)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9721091)** *Science* 1998, **281:**1312-1316.
- 5. Nicholson DW, Thornberry NA: **[Caspases: killer proteases](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1016/S0968-0004(97)01085-2)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9270303)** *Trends Biochem Sci* 1997, **22:**299-306.
- 6. Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, McCutcheon K, Salvesen GS, Propp SS, Bromm M, Rowland KJ, Zhang T, Rasper D, Roy S, Thornberry N, Pinsky L, Kakizuka A, Ross CA, Nicholson DW, Bredesen DE, Hayden MR: **[Caspase](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.273.15.9158) [cleavage of gene products associated with triplet expansion](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.273.15.9158) disorders generates truncated fragments containing the pol[yglutamine tract](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.273.15.9158)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9535906)** *J Biol Chem* 1998, **273:**9158-9167.
- 7. Kim TW, Pettingell WH, Jung YK, Kovacs DM, Tanzi RE: **[Alterna](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1126/science.277.5324.373)[tive cleavage of Alzheimer-associated presenilins during](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1126/science.277.5324.373) [apoptosis by a caspase-3 family protease](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1126/science.277.5324.373)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9219695)** *Science* 1997, **277:**373-376.
- 8. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW: **[Involvement of caspases in proteo](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1016/S0092-8674(00)80748-5)[lytic cleavage of Alzheimer's amyloid-beta precursor protein](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1016/S0092-8674(00)80748-5) [and amyloidogenic A beta peptide formation](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1016/S0092-8674(00)80748-5)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10319819)** *Cell* 1999, **97:**395-406.
- 9. Thompson CB: **[Apoptosis in the pathogenesis and treatment](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7878464) [of disease.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7878464)** *Science* 1995, **267:**1456-1462.
- 10. Wilson KP, Black JF, Thomson JA, Kim EE, Griffith JP, Navia MA, Murcko MA, Chambers SP, Aldape RA, Raybuck SA, Livingston DJ: **[Structure and mechanism of interleukin-1 beta converting](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1038/370270a0) [enzyme](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1038/370270a0)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8035875)** *Nature* 1994, **370:**270-275.
- 11. Walker NPC, Talanian RV, Brady KD, Dang LC, Bump NJ, Ferenz CR, Franklin S, Ghayur T, Hackett MC, Hammil LD, Herzog L, Hugunin M, Houy W, Mankovich JA, McGuiness L, Oriewicz E, Paskind M, Pratt CA, Reis P, Summani A, Terranova M, Welch JP, Xiong L, Moller A, Tracey DE, Kamen R, Wong WW: **[Crystal structure of the](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1016/0092-8674(94)90303-4) [cysteine protease interleukin-1 beta-converting enzyme: a](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1016/0092-8674(94)90303-4) [\(p20/p10\)2 homodimer](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1016/0092-8674(94)90303-4)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8044845)** *Cell* 1994, **78:**343-352.
- 12. Rotonda J, Nicholson DW, Fazil KM, Gallant M, Gareau Y, Labelle M, Peterson EP, Rasper DM, Ruel R, Vaillancourt JP, Thornberry NA, Becker JW: **[The three-dimensional structure of apopain/](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8673606) [CPP32, a key mediator of apoptosis.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8673606)** *Nature Struct Biol* 1996, **3:**619-625.
- 13. Mittl PRE, Di Marco S, Krebs JF, Bai X, Karanewsky DS, Priestle JP, Tomaselli KJ, Grutter MG: **[Structure of recombinant human](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.272.10.6539) [CPP32 in complex with the tetrapeptide acetyl-Asp-Val-Ala-](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.272.10.6539)[Asp fluoromethyl ketone](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.272.10.6539)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9045680)** *J Biol Chem* 1997, **272:**6539-6547.
- 14. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, Houtzager VM, Nordstrom PA, Roy S, Vaillancourt JP, Chapman KT, Nicholson DW: **[A combinatorial approach defines](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.272.29.17907) [specificities of members of the caspase family and granzyme](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.272.29.17907) B. Functional relationships established for key mediators of [apoptosis](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.272.29.17907)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9218414)** *J Biol Chem* 1997, **272:**17907-17911.
- 15. Humke EW, Ni J, Dixit VM: **[ERICE, a novel FLICE-activatable](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.273.25.15702) [caspase](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.273.25.15702)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9624166)** *J Biol Chem* 1998, **273:**15702-15707.
- 16. Shimin H, Snipas SJ, Vincenz C, Salvesen G, Dixit VM: **[Caspase-14 is](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.273.45.29648) [a novel developmentally regulated protease](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.273.45.29648)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9792675)** *J Biol Chem* 1998, **273:**29648-29653.
- 17. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC: **[Cleavage of poly\(ADP-ribose\) polymerase by a proteinase](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1038/371346a0) [with properties like ICE](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1038/371346a0)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8090205)** *Nature* 1994, **371:**346-347.
- 18. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA: **[Inhibition of human caspases by peptide](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.273.49.32608)[based and macromolecular inhibitors](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.273.49.32608)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9829999)** *J Biol Chem* 1998, **273:**32608-32613.
- 19. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ: **[Automated Docking Using a Lamarckian Genetic](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B) [Algorithm and and Empirical Binding Free Energy Function.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B)** *J Comput Chem* 1998, **19:**1639-1662.
- 20. Chou KC, Tomasselli AG, Reardon IM, Heinrikson RL: **[Predicting](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1002/(SICI)1097-0134(199601)24:1<51::AID-PROT4>3.0.CO;2-R) [human immunodeficiency virus protease cleavage sites in](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1002/(SICI)1097-0134(199601)24:1<51::AID-PROT4>3.0.CO;2-R) [proteins by a discriminant function method](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1002/(SICI)1097-0134(199601)24:1<51::AID-PROT4>3.0.CO;2-R)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8628733)** *Proteins* 1996, **24:**51-72.
- 21. Poorman RA, Tomasselli AG, Heinrikson RL, Kezdy FJ: [A cumula](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=1860861)**[tive specificity model for proteases from human immunode](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=1860861)ficiency virus types 1 and 2, inferred from statistical analysis [of an extended substrate data base.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=1860861)** *J Biol Chem* 1991, **266:**14554-61.
- 22. Rosin CD, Belew RK, Morris GM, Olson AJ, Goodsell DS: **[Coevolu](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1073/pnas.96.4.1369)[tionary analysis of resistance-evading peptidomimetic inhib](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1073/pnas.96.4.1369)[itors of HIV-1 protease](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1073/pnas.96.4.1369)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9990030)** *Proc Natl Acad Sci U S A* 1999, **96:**1369-1374.
- 23. Hetenyi C, van der Spoel D: **[Efficient docking of peptides to pro](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1110/ps.0202302)[teins without prior knowledge of the binding site](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1110/ps.0202302)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12070326)** *Protein Sci* 2002, **11:**1729-1737.
- 24. Ponder JW, Richards FM: **An Efficient Newton-like Method for Molecular Mechanics Energy Minimization of Large Molecules.** *J Comput Chem* 1987, **8:**1016-1024.
- 25. Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, Bromm M, Kazemi-Esfarjani P, Thornberry NA, Vaillancourt JP, Hayden MR: **[Cleavage of huntingtin by apopain, a](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8696339) [proapoptotic cysteine protease, is modulated by the poly](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8696339)[glutamine tract.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8696339)** *Nat Genet* 1996, **13:**442-449.
- 26. The RCSB Protein Data Bank: [\[http://www.rcsb.org/pdb/\]](http://www.rcsb.org/pdb/).
- 27. Nissink JW, Murray C, Hartshorn M, Verdonk ML, Cole JC, Taylor R: **[A new test set for validating predictions of protein-ligand](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1002/prot.10232) [interaction](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1002/prot.10232)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=12402356)** *Proteins* 2002, **49:**457-71.
- 28. Zhao Y, Gran B, Pinilla C, Markovic-Plese S, Hemmer B, Tzou A, Whitney LW, Biddison WE, Martin R, Simon R: **[Combinatorial](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11489997) peptide libraries and biometric score matrices permit the [quantitative analysis of specific and degenerate interactions](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11489997) [between clonotypic TCR and MHC peptide ligands.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11489997)** *J Immunol* 2001, **167:**2130-41.
- 29. Sakahira H, Enari M, Nagata S: **[Cleavage of CAD inhibitor in CAD](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1038/34214) [activation and DNA degradation during apoptosis](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1038/34214)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=9422513)** *Nature* 1998, **391:**96-99.
- 30. Song Q, Lees-Miller SP, Kumar S, Zhang Z, Chan DW, Smith GC, Jackson SP, Alnemri ES, Litwack G, Khanna KK, Lavin MF: **[DNA](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8670824)[dependent protein kinase catalytic subunit: a target for an](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8670824) [ICE-like protease in apoptosis.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8670824)** *EMBO J* 1996, **15:**3238-3246.
- 31. Waterhouse N, Kumar S, Song Q, Strike P, Sparrow L, Dreyfuss G, Alnemri ES, Litwack G, Lavin M, Watters D: **[Heteronuclear ribo](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.271.46.29335)[nucleoproteins C1 and C2, components of the spliceosome,](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.271.46.29335) are specific targets of interleukin 1beta-converting enzyme[like proteases in apoptosis](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1074/jbc.271.46.29335)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8910595)** *J Biol Chem* 1996, **271:**29335-29341.
- 32. Emoto Y, Manome Y, Meinhardt G, Kisaki H, Kharbanda S, Robertson M, Ghayur T, Wong WW, Kamen R, Weichselbaum R, Kufe D: **[Pro](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8557034)[teolytic activation of protein kinase C delta by an ICE-like](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8557034) [protease in apoptotic cells.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8557034)** *EMBO J* 1995, **14:**6148-6156.
- 33. Ghayur T, Hugunin M, Talanian RV, Ratnofsky S, Quinlan C, Emoto Y, Pandey P, Datta R, Huang Y, Kharbanda S, Allen H, Kamen R, Wong W, Kufe D: **[Proteolytic activation of protein kinase C delta by](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1084/jem.184.6.2399) [an ICE/CED 3-like protease induces characteristics of](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1084/jem.184.6.2399) [apoptosis](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10.1084/jem.184.6.2399)[.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8976194)** *J Exp Med* 1996, **184:**2399-2404.
- 34. Wang ZQ, Auer B, Stingl L, Berghammer H, Haidacher D, Schweiger M, Wagner EF: **[Mice lacking ADPRT and poly\(ADP-ribo](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7698643)[syl\)ation develop normally but are susceptible to skin](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7698643) [disease.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7698643)** *Genes Dev* 1995, **9:**509-520.
- 35. Browne SJ, Williams AC, Hague A, Butt AJ, Paraskeva C: **[Loss of](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7927905) APC protein expressed by human colonic epithelial cells and [the appearance of a specific low-molecular-weight form is](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7927905) [associated with apoptosis in vitro.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=7927905)** *Int J Cancer* 1994, **59:**56-64.
- 36. An B, Dou QP: **[Cleavage of retinoblastoma protein during](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8564948) [apoptosis: an interleukin 1 beta-converting enzyme-like pro](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8564948)[tease as candidate.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8564948)** *Cancer Res* 1996, **56:**438-442.

